Hikal Limited has informed the Exchange about Presentation
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Hikal Limited reported Q4 FY26 revenue of Rs. 519 Cr with EBITDA margin of 20.3%, a meaningful improvement from Q3's 16.8%. For full year FY26, revenue stood at Rs. 1,713 Cr with EBITDA margin of 12.9% (vs 17.7% in FY25), and PAT of Rs. 49 Cr including exceptional items of Rs. 85 Cr (labour code impact Rs. 38 Cr + Panoli asset impairment Rs. 47 Cr). Pharmaceuticals segment (Rs. 692 Cr revenue) recovered from H1 regulatory headwinds with improving CDMO pipeline and DMF filings increasing to 5-6 annually. Crop Protection (Rs. 1,021 Cr revenue) showed volume recovery but faces ongoing pricing pressure from Chinese competition. New strategic investments in HPAPI lab at Pune and pilot plant at Panoli are now operational. Diversification into Personal Care and Specialty Chemicals is on track for FY27 commercialization.
Q4 performance signals the company is transitioning from remediation mode to sustainable growth, with improved margins and expanding CDMO pipeline. However, full-year margin compression and asset impairment charges remain concerns for FY26 shareholders.